€ 30.000 ter ondersteuning van innovatief denken voor verbetering van het welzijn van rundvee op bedrijfsniveau

Dynamic, open, personal: From today forward, these attributes will be the new public face of the Bayer brand.

• · Comprehensive study recently published in Current Biology
  · Research findings will improve Bayer’s ability to develop new selective insecticides

Group sales increased by 1.5 percent (Fx & portfolio adj.) to 35.015 billion euros / Another record year for Pharmaceuticals / Weak business development at Consumer Health / Crop Science business down against prior year due to situation in Brazil – measures taking effect / EBITDA before special items level year on year at 9.288 billion euros / Net income raised by 61.9 percent to 7.336 billion euros / Core earnings per share increased by 1.0 percent to 6.74 euros / Covestro deconsolidated – additional cash inflows of 4.7 billion euros / Monsanto acquisition expected to close in second quarter of 2018 / Group outlook for 2018: increase in sales (Fx & portfolio adj.), EBITDA before special items and core earnings per share at prior-year level due to currency effects